Experimental study of antiangiogenic and photodynamic therapies combination for treatment of peritoneal carcinomatosis: Preliminary results

Experimental Oncology

Volumn 32, Issue 2, 2010, Pages 100-103

  Piatrouskaya, N A ^a   Kharuzhyk, S A ^a   Vozmitel, M A ^a   Mazurenko, A N ^a   Istomin, Y P ^a  

^a NN Alexandrov National Cancer Center of Belarus   (Belarus)

Author keywords

Antiangiogenic therapy; Intraperitoneal photodynamic therapy; Orthotopic model; Peritoneal carcinomatosis

Indexed keywords

BEVACIZUMAB; CHLORIN E6 POLYVINYLPYRROLIDONE CONJUGATE; EVANS BLUE; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER MODEL; CANCER TRANSPLANTATION; CARCINOMATOUS PERITONITIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; INFLAMMATION; MONITORING; MORPHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; RAT; TREATMENT OUTCOME; TUMOR NECROSIS; VITAL STAIN;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DISEASE MODELS, ANIMAL; NEOPLASM TRANSPLANTATION; PERITONEAL NEOPLASMS; PHOTOCHEMOTHERAPY; PILOT PROJECTS; RATS;

EID: 77954616955     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Sadeghi B, Arveux C, Glehen O. Peritoneal carcinomatosis from non-gynecologic malignancy. Cancer 2000; 88: 358-63.
2. Goldstein P, Silva RG, Cabanas J, et al. Management of peritoneal carcinomatosis from colon cancer, gastric cancer and appendix malignancy. Cancer Therapy 2005; 3: 299-320.
3. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005; 2: 3:
4. van der Vange N, van Goethem AR, Zoetmulder FAN, et al. Extensive cytoreductive surgerycombined with intra-operative intrapertoneal perfusion with cisplatin under hyperthermic condition (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 2000; 26: 663-8.
5. Hahn SM, Fraker DL, Mick R. A Phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res 2006; 8: 2517-25.
6. Solban N, Pal SK, Alok SK, et al. Mechanistic investigation and implication of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Res 2006; 66: 5633-40. (Pubitemid 43927115)
7. Kosharskyy B, Solban N, Chang SK, et al. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res 2006; 66: 10953-8. (Pubitemid 44876994)
8. Rai P, Chang SK, Mai Z, et al. Nanotechnology-based combination therapy improves treatment response in cancer models. Proc of SPIE 2009; 7380: 0W1-11.
9. Fleming JB, Brekken RA. Functional imaging of angiogenesis in an orthotopic model of pancreatic cancer. J Cel Biochem 2003; 90: 492-501.
10. Chen B, Pogue BW, Zhou X. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin Cancer Res 2005; 11: 720-7. (Pubitemid 40116900)
11. O'Hara J, Samkoe KS, Chen A. Uptake of verteporfin by orthotopic xenograft pancreas models with different levels of aggression. Proc of SPIE 2009; 7380: 5F-1-7.
12. Plaks V, Koudinova N, Nevo U. Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker. Neoplasia 2004; 6: 224-33.
13. Rehman S, Jayson GC. Molecular imaging of antiangiogenic agents. Oncologist 2005; 10: 93-103.
14. Padhany AR, Liu G, Mu-Koh D. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-25.